Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Hymecromone→

Hymecromone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
90-33-5
Molecular formula
C10H8O3
Molecular weight
176.1687 g/mol
Drug class
Coumarin derivativecholeretic and biliary smooth-muscle spasmolytic
Mechanism of action
Promotes bile flow and has reported spasmolytic activity in the biliary tract. Its precise molecular mechanism is not fully established.
Indications / reported uses
  • Symptomatic treatment of biliary tract spasm and dyspeptic symptoms associated with biliary dysfunction in countries where hymecromone is authorised.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68006923

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Hymecromone Environmental Risk Assessment (ERA) (the Hymecromone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.